International Journal of Cancer Management

Published by: Kowsar
Crossmark

The Radioprotective Effects of Nano-Curcumin Against Genotoxicity Induced by Iodine-131 in Patients with Differentiated Thyroid Carcinoma (DTC) by Micronucleus Assay

Maryam Farhadi 1 , Mohsen Bakhshandeh ORCID 1 , * , Babak Shafiei 2 , Aziz Mahmoudzadeh 3 and Seyed Jalal Hosseinimehr 4
Authors Information
1 Department of Radiology Technology, Faculty of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Nuclear Medicine, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Bioscience and Biotechnology, Malek_Ashtar University of Technology, Tehran, Iran
4 Department of Radiopharmacy, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Article information
  • International Journal of Cancer Management: June 2018, 11 (6); e14193
  • Published Online: June 11, 2018
  • Article Type: Research Article
  • Received: July 12, 2017
  • Revised: March 12, 2017
  • Accepted: April 17, 2018
  • DOI: 10.5812/ijcm.14193

How to Cite: Farhadi M, Bakhshandeh M, Shafiei B, Mahmoudzadeh A, Hosseinimehr S J. The Radioprotective Effects of Nano-Curcumin Against Genotoxicity Induced by Iodine-131 in Patients with Differentiated Thyroid Carcinoma (DTC) by Micronucleus Assay, Int J Cancer Manag. 2018 ; 11(6):e14193. doi: 10.5812/ijcm.14193.

Abstract
Copyright © 2018, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Shafaghati N, Hedayati M, Hosseinimehr SJ. Protective effects of curcumin against genotoxicity induced by 131-iodine in human cultured lymphocyte cells. Pharmacogn Mag. 2014;10(38):106-10. doi: 10.4103/0973-1296.131020. [PubMed: 24914274]. [PubMed Central: PMC4048555].
  • 2. Dardano A, Ballardin M, Caraccio N, Boni G, Traino C, Mariani G, et al. The effect of Ginkgo biloba extract on genotoxic damage in patients with differentiated thyroid carcinoma receiving thyroid remnant ablation with iodine-131. Thyroid. 2012;22(3):318-24. doi: 10.1089/thy.2010.0398. [PubMed: 22181338].
  • 3. Hosseinimehr SJ. Flavonoids and genomic instability induced by ionizing radiation. Drug Discov Today. 2010;15(21-22):907-18. doi: 10.1016/j.drudis.2010.09.005. [PubMed: 20933097].
  • 4. Bushnell DL, Boles MA, Kaufman GE, Wadas MA, Barnes WE. Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. J Nucl Med. 1992;33(12):2214-21. [PubMed: 1460519].
  • 5. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009;19(12):1381-91. doi: 10.1089/thy.2009.1611. [PubMed: 20001720].
  • 6. Jarzab B, Handkiewicz-Junak D, Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer. 2005;12(4):773-803. doi: 10.1677/erc.1.00880. [PubMed: 16322322].
  • 7. Tuttle RM, Becker DV, Hurley JR. Radioiodine treatment of thyroid disease. In: Sandler MP, Coleman RE, Patton JE, Wackers FJT, Gottschalk A, editors. Diagnostic nuclear medicine. 2003.
  • 8. Fard-Esfahani A, Emami-Ardekani A, Fallahi B, Fard-Esfahani P, Beiki D, Hassanzadeh-Rad A, et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun. 2014;35(8):808-17. doi: 10.1097/MNM.0000000000000132. [PubMed: 24751702].
  • 9. Baugnet-Mahieu L, Lemaire M, Leonard ED, Leonard A, Gerber GB. Chromosome aberrations after treatment with radioactive iodine for thyroid cancer. Radiat Res. 1994;140(3):429-31. doi: 10.2307/3579122. [PubMed: 7972697].
  • 10. Watanabe N, Kanegane H, Kinuya S, Shuke N, Yokoyama K, Kato H, et al. The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes. J Nucl Med. 2004;45(4):608-11. [PubMed: 15073256].
  • 11. Little JB. Radiation carcinogenesis. Carcinogenesis. 2000;21(3):397-404. doi: 10.1093/carcin/21.3.397. [PubMed: 10688860].
  • 12. Noaparast Z, Hosseinimehr SJ. Radioprotective agents for the prevention of side effects induced by radioiodine-131 therapy. Future Oncol. 2013;9(8):1145-59. doi: 10.2217/fon.13.79. [PubMed: 23902246].
  • 13. Garg AK, Buchholz TA, Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid Redox Signal. 2005;7(11-12):1630-47. doi: 10.1089/ars.2005.7.1630. [PubMed: 16356126].
  • 14. Hejazi J, Rastmanesh R, Taleban FA, Molana SH, Ehtejab G. A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer. J Cancer Sci Ther. 2013;5(10):320-4. doi: 10.4172/1948-5956.1000222.
  • 15. Jagetia GC, Rajanikant GK. Effect of curcumin on radiation-impaired healing of excisional wounds in mice. J Wound Care. 2004;13(3):107-9. doi: 10.12968/jowc.2004.13.3.26589. [PubMed: 15045805].
  • 16. Jagetia GC, Rajanikant GK. Acceleration of wound repair by curcumin in the excision wound of mice exposed to different doses of fractionated gamma radiation. Int Wound J. 2012;9(1):76-92. doi: 10.1111/j.1742-481X.2011.00848.x. [PubMed: 21883936].
  • 17. Ozgen SC, Dokmeci D, Akpolat M, Karadag CH, Gunduz O, Erbas H, et al. The Protective Effect of Curcumin on Ionizing Radiation-induced Cataractogenesis in Rats. Balkan Med J. 2012;29(4):358-63. doi: 10.5152/balkanmedj.2012.038. [PubMed: 25207034]. [PubMed Central: PMC4115869].
  • 18. Flora G, Gupta D, Tiwari A. Preventive efficacy of bulk and nanocurcumin against lead-induced oxidative stress in mice. Biol Trace Elem Res. 2013;152(1):31-40. doi: 10.1007/s12011-012-9586-3. [PubMed: 23292317].
  • 19. Yadav A, Lomash V, Samim M, Flora SJ. Curcumin encapsulated in chitosan nanoparticles: a novel strategy for the treatment of arsenic toxicity. Chem Biol Interact. 2012;199(1):49-61. doi: 10.1016/j.cbi.2012.05.011. [PubMed: 22704994].
  • 20. Mateuca R, Lombaert N, Aka PV, Decordier I, Kirsch-Volders M. Chromosomal changes: induction, detection methods and applicability in human biomonitoring. Biochimie. 2006;88(11):1515-31. doi: 10.1016/j.biochi.2006.07.004. [PubMed: 16919864].
  • 21. Hosseinimehr SJ, Shafaghati N, Hedayati M. Genotoxicity induced by iodine-131 in human cultured lymphocytes. Interdiscip Toxicol. 2013;6(2):74-6. doi: 10.2478/intox-2013-0013. [PubMed: 24179432]. [PubMed Central: PMC3798859].
  • 22. Gutierrez S, Carbonell E, Galofre P, Creus A, Marcos R. Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer. A study using the micronucleus test. Eur J Nucl Med. 1999;26(12):1589-96. doi: 10.1007/s002590050499. [PubMed: 10638411].
  • 23. Ebrahimnejad P, Dinarvand R, Jafari MR, Tabasi SA, Atyabi F. Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38. Int J Pharm. 2011;406(1-2):122-7. doi: 10.1016/j.ijpharm.2010.12.022. [PubMed: 21185365].
  • 24. Fenech M. The in vitro micronucleus technique. Mutat Res. 2000;455(1-2):81-95. [PubMed: 11113469].
  • 25. American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS, Doherty GM, Haugen BR, Kloos RT, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214. doi: 10.1089/thy.2009.0110. [PubMed: 19860577].
  • 26. Monteiro Gil O, Oliveira NG, Rodrigues AS, Laires A, Ferreira TC, Limbert E, et al. Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy. Mutagenesis. 2000;15(1):69-75. doi: 10.1093/mutage/15.1.69. [PubMed: 10640533].
  • 27. Ballardin M, Gemignani F, Bodei L, Mariani G, Ferdeghini M, Rossi AM, et al. Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131. Mutat Res. 2002;514(1-2):77-85. doi: 10.1016/S1383-5718(01)00323-0. [PubMed: 11815246].
  • 28. Nofal MM, Beierwaltes WH. Persistent Chromosomal Aberrations Following Radioiodine Therapy. J Nucl Med. 1964;5:840-50. [PubMed: 14247780].
  • 29. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491-9. doi: 10.1158/1078-0432.CCR-08-0024. [PubMed: 18628464].
  • 30. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol. 2011;68(1):157-64. doi: 10.1007/s00280-010-1470-2. [PubMed: 20859741].
  • 31. Tsai YM, Chien CF, Lin LC, Tsai TH. Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharm. 2011;416(1):331-8. doi: 10.1016/j.ijpharm.2011.06.030. [PubMed: 21729743].
  • 32. Zhongfa L, Chiu M, Wang J, Chen W, Yen W, Fan-Havard P, et al. Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemother Pharmacol. 2012;69(3):679-89. doi: 10.1007/s00280-011-1749-y. [PubMed: 21968952]. [PubMed Central: PMC3368221].
  • 33. Wahlang B, Kabra D, Pawar YB, Tikoo K, Bansal AK. Contribution of formulation and excipients towards enhanced permeation of curcumin. Arzneimittelforschung. 2012;62(2):88-93. doi: 10.1055/s-0031-1295487. [PubMed: 22344553].
  • 34. Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53(10):1633-51. doi: 10.2967/jnumed.112.105148. [PubMed: 22787108].
  • 35. Dardano A, Ballardin M, Ferdeghini M, Lazzeri E, Traino C, Caraccio N, et al. Anticlastogenic effect of Ginkgo biloba extract in Graves' disease patients receiving radioiodine therapy. J Clin Endocrinol Metab. 2007;92(11):4286-9. doi: 10.1210/jc.2007-0597. [PubMed: 17711926].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments